ArticlePreventive medicine reports2026
Regional variation in maternal RSV vaccine access and attitudes across two California cohorts.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare maternal RSV vaccination rates, attitudes, and vaccine information sources between an urban academic hospital in San Francisco and a regional hospital serving a predominantly rural population in Fresno, California. Methods: Individuals eligible for RSV vaccination during pregnancy were recruited on postpartum units between 11/2024-3/2025 using convenience sampling. Participants completed a survey assessing vaccination status, attitudes, and information sources. Results: Of 149 approached patients, 94 completed the survey (63.09% response rate; San Francisco, 62/114 [54.39%]; Fresno, 32/35 [91.43%]). San Francisco participants were older (mean [SD], 36.11 [4.06] vs. 29.19 [5.60] years; Conclusions: Marked regional differences in maternal RSV vaccination highlight the need for system-level strategies to ensure equitable vaccine access and education, alongside continued vaccine safety research to build patient confidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.